Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Crizotinib Eases Past FDA With Targeted Population

Executive Summary

FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.
Advertisement

Related Content

Pharma R&D Productivity Shows Signs Of Progress
Pfizer Oncology Strategy: An Investment Starts To Pay Off
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
FDA Releases Companion Dx Guidance Broad In Scope, Limited In Detail
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
Fast As A Whip, Pfizer Files Personalized Lung Cancer Drug Crizotinib
Crizotinib Holds Promise For Lung Cancer, And For Pfizer Oncology

Topics

Advertisement
UsernamePublicRestriction

Register

PS053718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel